Loss in skeletal muscle mass during systemic therapy for NSCLC is a marker of poor outcomes, especially in male patients, suggest results of this multicohort study. https://ja.ma/4eovl9Y
JAMA Oncology’s Post
More Relevant Posts
-
Myelodysplastic syndrome mainly occurs in patients over the age of 60. If left untreated, it can lead to secondary #acutemyeloidleukemia. Read more in an article from Cureus Journal of Medical Science here: https://lnkd.in/eeKGRni6 #AML #AMLleukemia #bloodcancer
Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Patients Aged Over 60 Years
cureus.com
-
Can we spare local treatment for brain mets in patients where osimertinib is being used ? Local treatment plus osimertinib better than using osimertinib alone #osimertinib #lungcancer #lungcanertreatment
Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer
lungcancerjournal.info
-
Agnostic anti fgfr activity .congrats yohann: your work shows clinical benefit for erdafitinib in the tumour-agnostic setting in patients with advanced solid tumours with susceptible FGFR alterations
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
sciencedirect.com
-
The diagnostic and prognostic role of miR-146b-5p in differentiated thyroid carcinomas Frontiers https://lnkd.in/gAGd-Yka
Frontiers | The diagnostic and prognostic role of miR-146b-5p in differentiated thyroid carcinomas
frontiersin.org
-
Lung adenocarcinoma in a patient with Lynch syndrome: a case report and literature review https://lnkd.in/dzK--hUm
Lung adenocarcinoma in a patient with Lynch syndrome: a case report and literature review
frontiersin.org
-
New research from the University of Maryland School of Medicine is exploring the possibility of a less toxic CAR T-cell therapy. New advancements are making this innovative approach to therapy safer and more accessible to a wider range of patients. Risks still remain, however. One such risk to patients who undergo CAR T-cell therapy is a potentially life-threatening side effect knowns as Cytokine Release Syndrome (CRS) an overreaction of the immune system. CytoAgents’ drug candidate reduces the cytokines generated during CRS while enabling the body to maintain appropriate cytokine levels. Reducing the rates and severity of toxicity allows for the treatment of more patients, treatment in the outpatient setting, and the decrease of treatment-related morbidity. #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh
New Innovation in CAR T-Cells Paves Way for Less Toxic Therapy Against Multiple Myeloma
newswise.com
-
📰 New study alert! 🩺 Understanding bleeding risks in cancer-associated venous thromboembolism (Ca-VTE) patients is crucial. The B-CAT score, developed from real-world data, shows promise in predicting significant bleeding events during anticoagulant therapy. More research is needed to assess long-term bleeding risks beyond the initial 6-month period. #thrombosis #thromboembolism #Healthcare Read more ⬇️
New Predictive Model for Bleeding in Anticoagulated VTE Cancer Patients – (B-CAT Score) - Icthic Magazine
https://magazine.icthic.com
-
Discover the innovative potential of targeting lymphatic function in cardiovascular-kidney-metabolic (CKM) syndrome! The article explores how enhancing lymphatic function could revolutionize treatment by addressing multiple pathologies simultaneously. Learn more about promising therapeutic targets that might shape the future of CKM therapy. Read the full article here 🔗 https://bit.ly/3VT0LwT #CaReMeO2024 #diabetes #cardiovasculardisease #renaldisease #primarycarephysicians
Targeting lymphatic function in CKM syndrome
frontiersin.org
Explorer, MD, PhD | Physician, Scientist, Clinical Informatics, DEI Health, VP Inclusivity, Board Member, Advisor, Consultant
2wwhat medical device FDA approval is this paper needed for? such an impressive collection of study centers, except there is no new knowledge in this paper. i am assuming this sub-JAMA journal had to approve it based on author politics, but i am very curious why you need this specific paper for AstraZeneca, restating decades of what is already known for all hospital (and non-hospital) patients for every disease? All the emerging NSCLC antibody therapies, the FDA will not approve for some reason without a NSCLC specific paper repeating the obvious?